Advertisement
Advertisement
RZLT
Rezolute, Inc. Common Stock (NV)
3.33
USDSponsored
+0.03
+0.91%
May 13, 16:00 UTC -4
Closed
Pre-Market
3.25
-0.08
-2.40%
RZLT Earnings Reports
Positive Surprise Ratio
RZLT beat 18 of 28 last estimates.
64%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Rezolute, Inc. Common Stock (NV) earnings per share and revenue
On May 12, 2026, RZLT reported earnings of -0.16 USD per share (EPS) for Q3 26, beating the estimate of -0.18 USD, resulting in a 12.33% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.91% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Rezolute, Inc. Common Stock (NV)'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Rezolute, Inc. Common Stock (NV) reported EPS of -$0.16, beating estimates by 12.33%, and revenue of $0.00, 0% as expectations.
How did the market react to Rezolute, Inc. Common Stock (NV)'s Q3 2026 earnings?
The stock price moved up 0.91%, changed from $3.30 before the earnings release to $3.33 the day after.
When is Rezolute, Inc. Common Stock (NV) expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Rezolute, Inc. Common Stock (NV)'s next earnings report?
Based on --
analysts, Rezolute, Inc. Common Stock (NV) is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement